What Causes Chronic Post-Nasal Drip — and How Do You Stop It?

Dr. Franklyn Gergits, ENT

Short answer: Chronic post-nasal drip is not a diagnosis — it is a symptom with multiple distinct causes. The most common are allergy, nonallergic rhinitis, laryngopharyngeal reflux, and chronic sinusitis. Each requires a different treatment approach, and treating the wrong one produces no improvement. A published three-year study of NEUROMARK® posterior nasal nerve treatment found a 50 percent reduction in post-nasal drainage scores and a 69 percent reduction in cough in patients with posterior nasal nerve-driven drainage. But that treatment is only appropriate when the posterior nasal nerve network is the driver — which is why the evaluation comes first.

What Post-Nasal Drip Actually Is

The nasal mucosa produces mucus continuously — roughly one to two liters per day in a healthy adult. Most of this mucus moves silently backward through the nasal cavity and down the throat via the mucociliary clearance system, where it is swallowed without any awareness. Post-nasal drip occurs when this process becomes abnormal — either because the volume of mucus produced increases, because the character of the mucus changes, because mucociliary clearance is impaired, or because the sensory nerve network of the posterior nasal cavity becomes hypersensitive and registers normal mucus flow as a subjective sensation of drainage.

An important nuance: research suggests that chronic post-nasal drip often involves increased mucus viscosity and impaired mucociliary clearance rather than simply overproduction. A 2019 study found no significant difference in the volume of nasal secretions between patients with post-nasal drip and healthy controls — but viscosity of nasal secretions was significantly increased in PND patients and was reversible during symptom-free intervals. Mucociliary clearance was also prolonged. In practical terms, this means the problem is frequently that mucus is too thick and moves too slowly — not that there is too much of it. This directly explains why hydration, saline irrigation, and treatments that restore normal mucociliary function often provide more relief than medications aimed at reducing mucus production.

That last cause — posterior nasal nerve hypersensitivity — is one of the most clinically significant and least recognized. Patients in this category produce a normal or only slightly elevated volume of mucus, but the posterior nasal nerve network fires in response to that mucus as if there were far more of it. The result is a constant sensation of drainage that is real to the patient but not fully explained by the volume of mucus actually present.

The Most Common Causes — and How to Distinguish Them

Allergy-driven drainage is the most common identifiable cause of chronic post-nasal drip. Allergen exposure triggers mast cell degranulation and release of histamine and other inflammatory mediators that increase mucus production and alter its character. The drainage is typically thin and watery, frequently accompanied by sneezing, nasal itching, and eye symptoms. In Scottsdale, Phoenix, and the greater Maricopa County area, the extended pollen seasons and specific desert allergen profile — desert broom, olive, mulberry, Bermuda grass, and dust mite — keep many patients in a state of near-constant allergic stimulation that drives persistent drainage year-round. This type responds to antihistamines and intranasal corticosteroids when the allergic driver is appropriately identified and treated. One important nuance: up to 50 percent of patients with chronic rhinitis have mixed rhinitis — both allergic and nonallergic components active simultaneously. This explains why many patients get only partial relief from allergy-directed therapy alone and continue to have breakthrough drainage despite appropriate antihistamine or immunotherapy treatment.

Nonallergic or vasomotor rhinitis produces drainage triggered by irritants, temperature changes, humidity shifts, strong odors, and barometric pressure changes rather than allergens. Allergy testing is negative. The drainage is often thick and mucoid rather than thin and watery, and it does not respond to antihistamines the way allergic drainage does. Intranasal antihistamines — azelastine — are more effective for nonallergic rhinitis than oral antihistamines, and intranasal ipratropium can reduce excessive mucus production specifically from this mechanism.

Laryngopharyngeal reflux is a cause that most patients have never been told about. Pepsin from the stomach reaching the posterior nasal cavity triggers mucosal inflammation and increased secretory activity. The drainage produced by LPR tends to be thick, sticky, and difficult to clear — patients frequently describe it as mucus that “never goes anywhere” regardless of how often they clear their throat. The throat clearing itself becomes a habitual response that can persist even after the underlying reflux is treated. LPR is also the most common cause of chronic cough in nonsmoking adults — a connection that most patients never make. Growing evidence including a 2024 systematic review and meta-analysis confirms a significant association between GERD and chronic sinonasal symptoms, with improvement on anti-reflux therapy in the majority of evaluated patients. An important clinical shift: the 2026 San Diego Consensus now recommends upfront objective testing rather than empiric acid suppression alone for isolated laryngopharyngeal symptoms — aligning with our practice’s “evaluation before treatment” philosophy rather than simply starting a PPI and waiting to see what happens.

Chronic sinusitis produces drainage from infected or inflamed sinuses that pools in the nasopharynx. This type is typically associated with other sinus symptoms — congestion, facial pressure, reduced smell — and is confirmed by nasal endoscopy and CT imaging rather than symptoms alone.

Posterior nasal nerve hypersensitivity is the driver for patients whose drainage sensation is disproportionate to the findings on examination and imaging — patients with normal or near-normal endoscopy and CT who still experience significant, life-affecting drainage. This is the patient population where NEUROMARK® posterior nasal nerve treatment is most appropriate and produces the most consistent benefit.

What NEUROMARK® Does — and Who It Helps

NEUROMARK® is an FDA-cleared in-office procedure that uses temperature-controlled radiofrequency energy delivered transnasally to treat the posterior nasal nerve network. These nerves — branches of the vidian nerve and the posterior nasal nerve — control mucus secretion and vascular tone in the posterior nasal cavity. When they become chronically hyperstimulated, the result is persistent drainage, post-nasal drip, and chronic rhinorrhea that does not respond adequately to medications.

A published three-year outcomes study found that NEUROMARK® produced a mean reduction in total nasal symptom scores of 4.5 points from a baseline of 7.8, with rhinorrhea specifically reduced by 55.8 percent and post-nasal drainage scores reduced by 50 percent at three years. Cough — a common downstream consequence of post-nasal drainage, and the most common cause of chronic cough in nonsmoking adults — was reduced by 69 percent. A 2024 systematic review and meta-analysis independently confirmed a pooled responder rate of 77 percent at three months and 81 percent at six months. Approximately 80 percent of appropriately selected patients notice meaningful improvement within the first three to six months.

A practical clinical pearl for patient selection: a 2025 Stanford study found that patients who respond to intranasal ipratropium — a medication that directly targets parasympathetic nerve-driven mucus secretion — had a significantly higher rate of meaningful improvement after in-office posterior nasal nerve ablation compared to non-responders (65 percent vs 28 percent, p = 0.03). If you have tried ipratropium nasal spray and found it helpful, that response may indicate you are a particularly strong candidate for NEUROMARK® and is worth discussing at your evaluation.

The procedure is performed in our office in North Scottsdale under local anesthesia — no hospital, no general anesthesia, same-day return to activity. It is not appropriate for every patient with post-nasal drip. It is most appropriate for patients whose drainage is driven primarily by posterior nasal nerve hypersensitivity — and the evaluation determines who that is.

The Right Sequence — Evaluation Before Treatment

Chronic post-nasal drip that has not responded to antihistamines, nasal sprays, or antibiotics is not treatment-resistant — it is diagnostically incomplete. The cause has not been identified. Nasal endoscopy, CT imaging when indicated, allergy testing, and a careful reflux history are the starting points for distinguishing the drivers and selecting the treatment that is actually right for you.

Want to Understand More?

This post is part of the Understanding Your Symptoms series on the Airway & Sinus Wellness Review.

→ What Is NEUROMARK® — and Could It Stop Your Chronic Runny Nose?

→ Will Balloon Sinuplasty Correct My Post-Nasal Drainage?

→ Why Antibiotics Keep Failing Your Sinus Infection

→ Is It Possible to Have Sinusitis Without Symptoms of a Cold?

→ Airway & Sinus Wellness Review — Full Publication

This post is part of the Understanding Your Symptoms section of the Airway & Sinus Wellness Review.

References

1. Piccirillo JF, Payne SC, Rosenfeld RM, et al. Clinical Practice Guideline: Adult Sinusitis Update. Otolaryngology–Head and Neck Surgery. 2025. entnet.org

2. Three-year NEUROMARK® outcomes data. Mean rTNSS reduction 4.5 points (baseline 7.8); rhinorrhea reduction 55.8%; post-nasal drainage reduction 50%; cough reduction 69%. Responder rate approximately 80% at 3–6 months.

3. Aldajani A, Alhussain F, Mesallam T, et al. Association between chronic rhinosinusitis and reflux diseases in adults: a systematic review and meta-analysis. American Journal of Rhinology & Allergy. 2024. Significant GERD-CRS association; improvement on anti-reflux therapy.

4. Dykewicz MS, Wallace DV, Amrol DJ, et al. Rhinitis 2020: a practice parameter update. Journal of Allergy and Clinical Immunology. 2020. Allergic vs nonallergic rhinitis; treatment distinctions; ipratropium for vasomotor rhinitis.

5. American Academy of Allergy, Asthma & Immunology. Allergic rhinitis — overview. AAAAI.org

6. Gergits FR. Posterior Sinonasal Syndrome (PSS). Preprint DOI: 10.20944/preprints202603.0858.v1. ORCID: 0009-0000-4893-6332.

7. Bucher MR, et al. Post-nasal drip involves increased mucus viscosity and prolonged mucociliary clearance rather than increased secretion volume — reversible during symptom-free intervals. Chest. 2019.

8. Bernstein JA, Bernstein JS, Makol R, Ward S. Allergic rhinitis: a review. JAMA. 2024. Up to 50% of chronic rhinitis patients have mixed allergic and nonallergic components.

9. 2024 systematic review and meta-analysis: radiofrequency neurolysis of the posterior nasal nerve. Pooled responder rate 77.1% at 3 months; 80.8% at 6 months; pooled rTNSS change -4.28 (95% CI -5.10 to -3.46).

10. Stanford study 2025. Ipratropium responders had significantly higher clinically meaningful improvement rate after in-office PNN ablation vs non-responders (64.7% vs 27.8%, p=0.03). Ipratropium response as practical predictor of NEUROMARK® candidacy.

11. 2026 San Diego Consensus. Recommends upfront objective testing rather than empiric PPI trial for isolated laryngopharyngeal symptoms — paradigm shift from empiric acid suppression approach.

About the Author

Dr. Franklyn R. Gergits, MBA, DO, FAOCO is a Board-Certified Otolaryngologist and Fellowship-Trained Otolaryngic Allergist with a Clinical Focus in Rhinology and Airway Disorders and over 30 years of clinical experience. He is the founder of the Sinus & Allergy Wellness Center of North Scottsdale, where he performs in-office balloon sinuplasty, turbinate reduction, NEUROMARK® posterior nasal nerve ablation, and Eustachian tube dilation under local anesthesia. He performed the first balloon sinuplasty in Pennsylvania and holds dual Entellus Centers of Excellence certifications. Dr. Gergits is the originator of the Posterior Sinonasal Syndrome (PSS) hypothesis — a clinical framework identifying pepsin-mediated posterior nasal mucosal injury as an upstream driver of chronic rhinosinusitis. Preprint available at Preprints.org (DOI: 10.20944/preprints202603.0858.v1). ORCID: 0009-0000-4893-6332.

SinusAndAllergyWellnessCenter.com · 480-525-8999

This content is for educational purposes only and does not constitute medical advice. If you have chronic post-nasal drip that has not responded to standard treatment, consult with a qualified otolaryngologist for a complete evaluation of potential underlying drivers.